<?xml version="1.0" encoding="UTF-8"?>
<p>Overall, apart from corticosteroids, the risks of IBD therapies, particularly 5‐ASAs and biologics, appear limited, and the importance of careful discussion regarding the risks versus benefits of medications with patients and among medical practitioners cannot be overstated. Inappropriate cessation of effective agents due to unjustified fear of adverse events may lead to IBD relapse, which when requiring the use of steroids or hospitalisation may inadvertently strain medical resources and increase the risk of COVID‐19 exposure and infection.</p>
